Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients.
CTC
Parsortix
cancer metastasis
circulating tumor cells
enrichment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Feb 2020
13 Feb 2020
Historique:
received:
06
01
2020
revised:
10
02
2020
accepted:
11
02
2020
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
20
2
2020
Statut:
epublish
Résumé
Circulating tumor cells (CTCs) are promising tools for risk prediction and the monitoring of response to therapy in cancer patients. Within the EU/IMI CANCER-ID consortium, we validated CTC enrichment systems for future inclusion into clinical trials. Due to the known heterogeneity of markers expressed on CTCs, we tested the Parsortix
Identifiants
pubmed: 32069934
pii: cancers12020442
doi: 10.3390/cancers12020442
pmc: PMC7072175
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Research Council
ID : 834974
Pays : International
Organisme : Innovative Medicines Initiative
ID : 115749
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 765492
Références
Anticancer Res. 2009 Oct;29(10):4185-7
pubmed: 19846970
Clin Chem. 2019 Apr;65(4):549-558
pubmed: 30737205
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Clin Cancer Res. 2007 Feb 1;13(3):920-8
pubmed: 17289886
Lancet Oncol. 2009 Mar;10(3):233-9
pubmed: 19213602
Eur J Cancer. 2019 Aug;117:60-68
pubmed: 31254940
PLoS One. 2015 Sep 23;10(9):e0138032
pubmed: 26397728
Int J Cancer. 2012 Feb 15;130(4):808-16
pubmed: 21387303
Analyst. 2016 Jan 21;141(2):669-78
pubmed: 26605519
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31212989
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Int J Cancer. 2016 Jun 15;138(12):2894-904
pubmed: 26789903
Transl Lung Cancer Res. 2017 Aug;6(4):431-443
pubmed: 28904887
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Cytometry A. 2007 Mar;71(3):154-62
pubmed: 17200956
Dev Cell. 2018 Apr 9;45(1):33-52.e12
pubmed: 29634935
Clin Chem. 2018 Mar;64(3):536-546
pubmed: 29301749
Clin Chem. 2016 Nov;62(11):1504-1515
pubmed: 27630154
Cancer Cell. 2013 May 13;23(5):573-81
pubmed: 23680145
EMBO Mol Med. 2014 Nov 14;7(1):1-11
pubmed: 25398926
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121
pubmed: 29355669
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Cancer Res. 2013 Apr 1;73(7):2059-69
pubmed: 23378342
Nat Rev Cancer. 2019 Oct;19(10):553-567
pubmed: 31455893
Cell. 2019 Jan 10;176(1-2):98-112.e14
pubmed: 30633912
Theranostics. 2017 Jun 25;7(10):2606-2619
pubmed: 28819450
PLoS One. 2014 Jan 08;9(1):e85264
pubmed: 24416373
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Cancer Metastasis Rev. 2016 Mar;35(1):41-8
pubmed: 26931653
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Cytometry A. 2018 Dec;93(12):1234-1239
pubmed: 30107082
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
J Oncol. 2010;2010:617421
pubmed: 20016752
Cancers (Basel). 2019 Oct 29;11(11):
pubmed: 31671846